FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer
Purpose: To assess the efficacy of 18Fluorodeoxyglucose-positron emission tomography (FDG-PET) for predicting a pathologic response in locally advanced esophageal cancer after neoadjuvant chemoradiotherapy. Methods and Materials: All enrolled patients were treated with neoadjuvant chemoradiotherapy...
Gespeichert in:
| Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2005-11, Vol.63 (4), p.1053-1059 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1059 |
|---|---|
| container_issue | 4 |
| container_start_page | 1053 |
| container_title | International journal of radiation oncology, biology, physics |
| container_volume | 63 |
| creator | Song, Si Yeol Kim, Jong Hoon Ryu, Jin Sook Lee, Gin Hyug Kim, Sung Bae Park, Seung Il Song, Ho-Young Cho, Kyung-Ja Ahn, Seung Do Lee, Sang-Wook Shin, Seong Soo Choi, Eun Kyung |
| description | Purpose: To assess the efficacy of
18Fluorodeoxyglucose-positron emission tomography (FDG-PET) for predicting a pathologic response in locally advanced esophageal cancer after neoadjuvant chemoradiotherapy.
Methods and Materials: All enrolled patients were treated with neoadjuvant chemoradiotherapy followed by esophagectomy and underwent two FDG-PET scans, before and after neoadjuvant chemoradiotherapy. We compared the results of the preoperative FDG-PET scans with the pathologic results.
Results: From July 2001 to July 2004, 32 patients (29 men and 3 women) were enrolled in this study. Pathologic complete response (pCR) in the esophagus was achieved in 21 of 32 patients (66%). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) in the primary tumors of the preoperative FDG-PET were 27%, 95%, 75%, and 71%, respectively. In regional lymph nodes, these values were 16%, 98%, 36%, and 93%, respectively. The mean standardized uptake value (SUV) of primary tumors was initially 5.6 ± 3.6 and changed to 1.5 ± 1.3 after neoadjuvant chemoradiotherapy (
p < 0.05). If analysis of metabolic response (SUV decrease, ΔSUV) was limited to initially highly metabolic primary tumors (SUV ≥4.0), pathologic response was correlated with metabolic response (
p = 0.006).
Conclusions: This study suggested that the pathologic response of an initially highly metabolic tumor after neoadjuvant chemoradiotherapy could be correlated with the metabolic response, and FDG-PET can provide additional information on tumor response to chemoradiotherapy. |
| doi_str_mv | 10.1016/j.ijrobp.2005.03.033 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68737008</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S036030160500564X</els_id><sourcerecordid>68737008</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-b8cf42381cb9f41aeed18d72ef51eff005c95b57a2f436718486a44d34c62a5a3</originalsourceid><addsrcrecordid>eNp9kMFq3DAQhkVpaDZp36AUnXqqN5Il2d5LoaRJWgi0hxR6E2NplJXRWq7kDewL5Lkjswu9BQbmMN_8w3yEfORszRlvroa1H1Lsp3XNmFozUUq8ISvetZtKKPX3LVkx0bBKFPicXOQ8MMY4b-U7cs7VppEtUyvyfPv9rvp980D9SOct0imh9Wb2caTR0QnmbQzx0RuaME9xzEjBzZjoiBHssH-CcaZmi7uYwPpYEhJMhyUsRAMhHCjYwhi0X5YENDP0ASnmOG3hESFQs0zTe3LmIGT8cOqX5M_tzcP1j-r-193P62_3lZF1M1d9Z5ysRcdNv3GSA6LlnW1rdIqjc0WE2ahetVA7KZqWd7JrQEorpGlqUCAuyedj7pTivz3mWe98NhgClIf2WTddK1rGugLKI2hSzDmh01PyO0gHzZle_OtBH_3rxb9mopQoa59O-ft-h_b_0kl4Ab4eASxfPnlMOhuPiyCfih1to3_9wgsLNpt3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68737008</pqid></control><display><type>article</type><title>FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Song, Si Yeol ; Kim, Jong Hoon ; Ryu, Jin Sook ; Lee, Gin Hyug ; Kim, Sung Bae ; Park, Seung Il ; Song, Ho-Young ; Cho, Kyung-Ja ; Ahn, Seung Do ; Lee, Sang-Wook ; Shin, Seong Soo ; Choi, Eun Kyung</creator><creatorcontrib>Song, Si Yeol ; Kim, Jong Hoon ; Ryu, Jin Sook ; Lee, Gin Hyug ; Kim, Sung Bae ; Park, Seung Il ; Song, Ho-Young ; Cho, Kyung-Ja ; Ahn, Seung Do ; Lee, Sang-Wook ; Shin, Seong Soo ; Choi, Eun Kyung</creatorcontrib><description>Purpose: To assess the efficacy of
18Fluorodeoxyglucose-positron emission tomography (FDG-PET) for predicting a pathologic response in locally advanced esophageal cancer after neoadjuvant chemoradiotherapy.
Methods and Materials: All enrolled patients were treated with neoadjuvant chemoradiotherapy followed by esophagectomy and underwent two FDG-PET scans, before and after neoadjuvant chemoradiotherapy. We compared the results of the preoperative FDG-PET scans with the pathologic results.
Results: From July 2001 to July 2004, 32 patients (29 men and 3 women) were enrolled in this study. Pathologic complete response (pCR) in the esophagus was achieved in 21 of 32 patients (66%). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) in the primary tumors of the preoperative FDG-PET were 27%, 95%, 75%, and 71%, respectively. In regional lymph nodes, these values were 16%, 98%, 36%, and 93%, respectively. The mean standardized uptake value (SUV) of primary tumors was initially 5.6 ± 3.6 and changed to 1.5 ± 1.3 after neoadjuvant chemoradiotherapy (
p < 0.05). If analysis of metabolic response (SUV decrease, ΔSUV) was limited to initially highly metabolic primary tumors (SUV ≥4.0), pathologic response was correlated with metabolic response (
p = 0.006).
Conclusions: This study suggested that the pathologic response of an initially highly metabolic tumor after neoadjuvant chemoradiotherapy could be correlated with the metabolic response, and FDG-PET can provide additional information on tumor response to chemoradiotherapy.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2005.03.033</identifier><identifier>PMID: 15964705</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Chemotherapy, Adjuvant ; Esophageal cancer ; Esophageal Neoplasms - diagnostic imaging ; Esophageal Neoplasms - drug therapy ; Esophageal Neoplasms - pathology ; Esophageal Neoplasms - radiotherapy ; Esophagectomy ; FDG-PET ; Female ; Fluorodeoxyglucose F18 ; Humans ; Male ; Middle Aged ; Pathologic response ; Positron-Emission Tomography ; Prospective Studies ; Radiopharmaceuticals ; Radiotherapy, Adjuvant ; Sensitivity and Specificity ; Treatment Outcome</subject><ispartof>International journal of radiation oncology, biology, physics, 2005-11, Vol.63 (4), p.1053-1059</ispartof><rights>2005 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c426t-b8cf42381cb9f41aeed18d72ef51eff005c95b57a2f436718486a44d34c62a5a3</citedby><cites>FETCH-LOGICAL-c426t-b8cf42381cb9f41aeed18d72ef51eff005c95b57a2f436718486a44d34c62a5a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijrobp.2005.03.033$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15964705$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Song, Si Yeol</creatorcontrib><creatorcontrib>Kim, Jong Hoon</creatorcontrib><creatorcontrib>Ryu, Jin Sook</creatorcontrib><creatorcontrib>Lee, Gin Hyug</creatorcontrib><creatorcontrib>Kim, Sung Bae</creatorcontrib><creatorcontrib>Park, Seung Il</creatorcontrib><creatorcontrib>Song, Ho-Young</creatorcontrib><creatorcontrib>Cho, Kyung-Ja</creatorcontrib><creatorcontrib>Ahn, Seung Do</creatorcontrib><creatorcontrib>Lee, Sang-Wook</creatorcontrib><creatorcontrib>Shin, Seong Soo</creatorcontrib><creatorcontrib>Choi, Eun Kyung</creatorcontrib><title>FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose: To assess the efficacy of
18Fluorodeoxyglucose-positron emission tomography (FDG-PET) for predicting a pathologic response in locally advanced esophageal cancer after neoadjuvant chemoradiotherapy.
Methods and Materials: All enrolled patients were treated with neoadjuvant chemoradiotherapy followed by esophagectomy and underwent two FDG-PET scans, before and after neoadjuvant chemoradiotherapy. We compared the results of the preoperative FDG-PET scans with the pathologic results.
Results: From July 2001 to July 2004, 32 patients (29 men and 3 women) were enrolled in this study. Pathologic complete response (pCR) in the esophagus was achieved in 21 of 32 patients (66%). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) in the primary tumors of the preoperative FDG-PET were 27%, 95%, 75%, and 71%, respectively. In regional lymph nodes, these values were 16%, 98%, 36%, and 93%, respectively. The mean standardized uptake value (SUV) of primary tumors was initially 5.6 ± 3.6 and changed to 1.5 ± 1.3 after neoadjuvant chemoradiotherapy (
p < 0.05). If analysis of metabolic response (SUV decrease, ΔSUV) was limited to initially highly metabolic primary tumors (SUV ≥4.0), pathologic response was correlated with metabolic response (
p = 0.006).
Conclusions: This study suggested that the pathologic response of an initially highly metabolic tumor after neoadjuvant chemoradiotherapy could be correlated with the metabolic response, and FDG-PET can provide additional information on tumor response to chemoradiotherapy.</description><subject>Aged</subject><subject>Chemotherapy, Adjuvant</subject><subject>Esophageal cancer</subject><subject>Esophageal Neoplasms - diagnostic imaging</subject><subject>Esophageal Neoplasms - drug therapy</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Esophageal Neoplasms - radiotherapy</subject><subject>Esophagectomy</subject><subject>FDG-PET</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pathologic response</subject><subject>Positron-Emission Tomography</subject><subject>Prospective Studies</subject><subject>Radiopharmaceuticals</subject><subject>Radiotherapy, Adjuvant</subject><subject>Sensitivity and Specificity</subject><subject>Treatment Outcome</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMFq3DAQhkVpaDZp36AUnXqqN5Il2d5LoaRJWgi0hxR6E2NplJXRWq7kDewL5Lkjswu9BQbmMN_8w3yEfORszRlvroa1H1Lsp3XNmFozUUq8ISvetZtKKPX3LVkx0bBKFPicXOQ8MMY4b-U7cs7VppEtUyvyfPv9rvp980D9SOct0imh9Wb2caTR0QnmbQzx0RuaME9xzEjBzZjoiBHssH-CcaZmi7uYwPpYEhJMhyUsRAMhHCjYwhi0X5YENDP0ASnmOG3hESFQs0zTe3LmIGT8cOqX5M_tzcP1j-r-193P62_3lZF1M1d9Z5ysRcdNv3GSA6LlnW1rdIqjc0WE2ahetVA7KZqWd7JrQEorpGlqUCAuyedj7pTivz3mWe98NhgClIf2WTddK1rGugLKI2hSzDmh01PyO0gHzZle_OtBH_3rxb9mopQoa59O-ft-h_b_0kl4Ab4eASxfPnlMOhuPiyCfih1to3_9wgsLNpt3</recordid><startdate>20051115</startdate><enddate>20051115</enddate><creator>Song, Si Yeol</creator><creator>Kim, Jong Hoon</creator><creator>Ryu, Jin Sook</creator><creator>Lee, Gin Hyug</creator><creator>Kim, Sung Bae</creator><creator>Park, Seung Il</creator><creator>Song, Ho-Young</creator><creator>Cho, Kyung-Ja</creator><creator>Ahn, Seung Do</creator><creator>Lee, Sang-Wook</creator><creator>Shin, Seong Soo</creator><creator>Choi, Eun Kyung</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20051115</creationdate><title>FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer</title><author>Song, Si Yeol ; Kim, Jong Hoon ; Ryu, Jin Sook ; Lee, Gin Hyug ; Kim, Sung Bae ; Park, Seung Il ; Song, Ho-Young ; Cho, Kyung-Ja ; Ahn, Seung Do ; Lee, Sang-Wook ; Shin, Seong Soo ; Choi, Eun Kyung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-b8cf42381cb9f41aeed18d72ef51eff005c95b57a2f436718486a44d34c62a5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Aged</topic><topic>Chemotherapy, Adjuvant</topic><topic>Esophageal cancer</topic><topic>Esophageal Neoplasms - diagnostic imaging</topic><topic>Esophageal Neoplasms - drug therapy</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Esophageal Neoplasms - radiotherapy</topic><topic>Esophagectomy</topic><topic>FDG-PET</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pathologic response</topic><topic>Positron-Emission Tomography</topic><topic>Prospective Studies</topic><topic>Radiopharmaceuticals</topic><topic>Radiotherapy, Adjuvant</topic><topic>Sensitivity and Specificity</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Song, Si Yeol</creatorcontrib><creatorcontrib>Kim, Jong Hoon</creatorcontrib><creatorcontrib>Ryu, Jin Sook</creatorcontrib><creatorcontrib>Lee, Gin Hyug</creatorcontrib><creatorcontrib>Kim, Sung Bae</creatorcontrib><creatorcontrib>Park, Seung Il</creatorcontrib><creatorcontrib>Song, Ho-Young</creatorcontrib><creatorcontrib>Cho, Kyung-Ja</creatorcontrib><creatorcontrib>Ahn, Seung Do</creatorcontrib><creatorcontrib>Lee, Sang-Wook</creatorcontrib><creatorcontrib>Shin, Seong Soo</creatorcontrib><creatorcontrib>Choi, Eun Kyung</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Song, Si Yeol</au><au>Kim, Jong Hoon</au><au>Ryu, Jin Sook</au><au>Lee, Gin Hyug</au><au>Kim, Sung Bae</au><au>Park, Seung Il</au><au>Song, Ho-Young</au><au>Cho, Kyung-Ja</au><au>Ahn, Seung Do</au><au>Lee, Sang-Wook</au><au>Shin, Seong Soo</au><au>Choi, Eun Kyung</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2005-11-15</date><risdate>2005</risdate><volume>63</volume><issue>4</issue><spage>1053</spage><epage>1059</epage><pages>1053-1059</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><abstract>Purpose: To assess the efficacy of
18Fluorodeoxyglucose-positron emission tomography (FDG-PET) for predicting a pathologic response in locally advanced esophageal cancer after neoadjuvant chemoradiotherapy.
Methods and Materials: All enrolled patients were treated with neoadjuvant chemoradiotherapy followed by esophagectomy and underwent two FDG-PET scans, before and after neoadjuvant chemoradiotherapy. We compared the results of the preoperative FDG-PET scans with the pathologic results.
Results: From July 2001 to July 2004, 32 patients (29 men and 3 women) were enrolled in this study. Pathologic complete response (pCR) in the esophagus was achieved in 21 of 32 patients (66%). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) in the primary tumors of the preoperative FDG-PET were 27%, 95%, 75%, and 71%, respectively. In regional lymph nodes, these values were 16%, 98%, 36%, and 93%, respectively. The mean standardized uptake value (SUV) of primary tumors was initially 5.6 ± 3.6 and changed to 1.5 ± 1.3 after neoadjuvant chemoradiotherapy (
p < 0.05). If analysis of metabolic response (SUV decrease, ΔSUV) was limited to initially highly metabolic primary tumors (SUV ≥4.0), pathologic response was correlated with metabolic response (
p = 0.006).
Conclusions: This study suggested that the pathologic response of an initially highly metabolic tumor after neoadjuvant chemoradiotherapy could be correlated with the metabolic response, and FDG-PET can provide additional information on tumor response to chemoradiotherapy.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>15964705</pmid><doi>10.1016/j.ijrobp.2005.03.033</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0360-3016 |
| ispartof | International journal of radiation oncology, biology, physics, 2005-11, Vol.63 (4), p.1053-1059 |
| issn | 0360-3016 1879-355X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68737008 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Chemotherapy, Adjuvant Esophageal cancer Esophageal Neoplasms - diagnostic imaging Esophageal Neoplasms - drug therapy Esophageal Neoplasms - pathology Esophageal Neoplasms - radiotherapy Esophagectomy FDG-PET Female Fluorodeoxyglucose F18 Humans Male Middle Aged Pathologic response Positron-Emission Tomography Prospective Studies Radiopharmaceuticals Radiotherapy, Adjuvant Sensitivity and Specificity Treatment Outcome |
| title | FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T20%3A00%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FDG-PET%20in%20the%20prediction%20of%20pathologic%20response%20after%20neoadjuvant%20chemoradiotherapy%20in%20locally%20advanced,%20resectable%20esophageal%20cancer&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Song,%20Si%20Yeol&rft.date=2005-11-15&rft.volume=63&rft.issue=4&rft.spage=1053&rft.epage=1059&rft.pages=1053-1059&rft.issn=0360-3016&rft.eissn=1879-355X&rft_id=info:doi/10.1016/j.ijrobp.2005.03.033&rft_dat=%3Cproquest_cross%3E68737008%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68737008&rft_id=info:pmid/15964705&rft_els_id=S036030160500564X&rfr_iscdi=true |